On March 28, 2022, we issued a Supplemental Proxy Statement, which includes additional information about how to vote regarding Proposal No. 1 to be voted on at the Special Meeting of Stockholders scheduled for March 31, 2022. The Supplemental Proxy Statement issued on March 28, 2022 is located

Presented Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones Priced Offering of $5 Million Convertible Redeemable Preferred Stock through a Private Placement MONMOUTH JUNCTION, N.J. , March 17, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc.

MONMOUTH JUNCTION, N.J. , Feb. 14, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc . (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announces its financial results for the fiscal year ended October 31, 2021 and provides

MONMOUTH JUNCTION, N.J., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc .  (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the Company entered into an agreement with certain institutional

Updated data show a second partial response in Part B Overall response rate of 15.4% and disease control rate of 46% in Part B with durable clinical benefit in patients with prior disease progression Preliminary data show disease control rate of 67% in first 3 patients in Part C, with ADXS-503

MONMOUTH JUNCTION, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the Company has satisfied the requirements for trading of the Company’s

Stockholders approved Proposal 1 in support of Biosight merger Proposal 2 reverse stock split, a condition for completing the merger of Advaxis and Biosight, was not approved MONMOUTH JUNCTION, N.J., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology

Stockholders passed Proposals 1 (the Merger) and 4 (Executive Compensation) Advaxis urges stockholders to vote “FOR” Proposal 2 at the upcoming special meeting in order to best position the company to build long term stockholder value MONMOUTH JUNCTION, N.J., Dec.

Company releases video message highlighting the need for all proposals to pass in order to consummate the proposed Biosight transaction Advaxis urges stockholders to vote “FOR” all of the proposals at the special meeting in order to best position the company to build long term stockholder value

MONMOUTH JUNCTION, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (“Advaxis” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products, announced that it has received a letter